Literature DB >> 20688518

S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase.

Kenji Matsuno1, Kazushige Takai, Yoshinobu Isaka, Yuka Unno, Masayuki Sato, Osamu Takikawa, Akira Asai.   

Abstract

S-benzylisothiourea 3a was discovered by its ability to inhibit indoleamine-2,3-dioxygenase (IDO) in our screening program. Subsequent optimization of the initial hit 3a lead to the identification of sub-muM inhibitors 3r and 10h, both of which suppressed kynurenine production in A431 cells. Synthesis and structure-activity relationship of S-benzylisothiourea analogues as small-molecule inhibitors of IDO are described. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20688518     DOI: 10.1016/j.bmcl.2010.07.025

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  10 in total

1.  O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1.

Authors:  William P Malachowski; Maria Winters; James B DuHadaway; Ariel Lewis-Ballester; Shorouk Badir; Jenny Wai; Maisha Rahman; Eesha Sheikh; Judith M LaLonde; Syun-Ru Yeh; George C Prendergast; Alexander J Muller
Journal:  Eur J Med Chem       Date:  2015-12-17       Impact factor: 6.514

Review 2.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

Review 3.  Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.

Authors:  Xiu-Xiu Wang; Si-Yu Sun; Qing-Qing Dong; Xiao-Xiang Wu; Wei Tang; Ya-Qun Xing
Journal:  Medchemcomm       Date:  2019-08-15       Impact factor: 3.597

4.  Fused Heterocyclic Compounds as Potent Indoleamine-2,3-dioxygenase 1 Inhibitors.

Authors:  Subhankar Panda; Ashalata Roy; Suman Jyoti Deka; Vishal Trivedi; Debasis Manna
Journal:  ACS Med Chem Lett       Date:  2016-10-15       Impact factor: 4.345

5.  Indole-Containing Amidinohydrazones as Nonpeptide, Dual RXFP3/4 Agonists: Synthesis, Structure-Activity Relationship, and Molecular Modeling Studies.

Authors:  Dongliang Guan; Md Toufiqur Rahman; Elaine A Gay; Vineetha Vasukuttan; Kelly M Mathews; Ann M Decker; Alexander H Williams; Chang-Guo Zhan; Chunyang Jin
Journal:  J Med Chem       Date:  2021-12-02       Impact factor: 7.446

6.  Discovery of Carbono(di)thioates as Indoleamine 2,3-Dioxygenase 1 Inhibitors.

Authors:  Miyuki Kumazawa; Manabu Tejima; Miwa Fukuda; Shota Takeda; Kenji Suzuki; Yukiko Mizumoto; Kakeru Sato; Minoru Waki; Hiroyuki Miyachi; Akira Asai; Osamu Takikawa; Tomoko Hashimoto; Osamu Ohno; Kenji Matsuno
Journal:  ACS Med Chem Lett       Date:  2021-01-15       Impact factor: 4.345

Review 7.  Major Developments in the Design of Inhibitors along the Kynurenine Pathway.

Authors:  Kelly R Jacobs; Gloria Castellano-Gonzalez; Gilles J Guillemin; David B Lovejoy
Journal:  Curr Med Chem       Date:  2017       Impact factor: 4.530

8.  4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth.

Authors:  Subhankar Panda; Nirmalya Pradhan; Soumya Chatterjee; Sudhir Morla; Abhishek Saha; Ashalata Roy; Sachin Kumar; Arindam Bhattacharyya; Debasis Manna
Journal:  Sci Rep       Date:  2019-12-05       Impact factor: 4.379

9.  Proapoptotic effects of novel pentabromobenzylisothioureas in human leukemia cell lines.

Authors:  Mirosława Koronkiewicz; Zdzisław Chilmonczyk; Zygmunt Kazimierczuk
Journal:  Med Chem Res       Date:  2011-11-11       Impact factor: 1.965

10.  Effects of various phytochemicals on indoleamine 2,3-dioxygenase 1 activity: galanal is a novel, competitive inhibitor of the enzyme.

Authors:  Rie Yamamoto; Yasuko Yamamoto; Shinjiro Imai; Ryuta Fukutomi; Yoshio Ozawa; Masako Abe; Yushi Matuo; Kuniaki Saito
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.